First Reflections on RDD 2026: FDA Guidance Updates Highlight Progress for  NGP pMDIs

Discover first reflections on RDD 2026 from Phoenix, Arizona, highlighting the impact of the research programme funded by FDA and exemplifying Nanopharm’s recognized scientific contributions to supporting the transition to next-generation propellant metered dose inhalers (pMDIs).